Skip to main content

Table 1 Patient characteristics

From: Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost

Age

 Median (IQR)

71 (68–74)

T-Stage (MRI or TRUS)

 1c

1 (5%)

 2a

12 (55%)

 2b

1 (5%)

 2c

3 (14%)

 3a

5 (23%)

Gleason

 3 + 3

1 (5%)

 3 + 4

9 (41%)

 4 + 3

9 (41%)

 4 + 5

1 (5%)

 5 + 4

2 (9%)

Pre-treatment PSA

 Median (IQR)

8.8 (5.8–9.5)

NCCN risk group

 Intermediate risk

13 (59%)

 High risk

7 (32%)

 Very high risk

2 (9%)

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us